Drugs.com
JUNE 2, 2025
MONDAY, June 2, 2025 Removing fluoride from the U.S. water supply could result in more than 25 million more decayed teeth in children and teenagers within five years, a new study warns.Thats the equivalent of a decayed tooth for 1 of every 3 kid.
Covalent Modifiers
JUNE 5, 2025
Gibae Kim, R. Justin Grams, and Ku-Lung Hsu Chemical Reviews 2025 DOI: 10.1021/acs.chemrev.5c00001 Targeting intractable proteins remains a key challenge in drug discovery, as these proteins often lack well-defined binding pockets or possess shallow surfaces not readily addressed by traditional drug design. Covalent chemistry has emerged as a powerful solution for accessing protein sites in difficult to ligand regions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
JUNE 6, 2025
As antibody-drug conjugates (ADCs) gain traction across oncology and begin to expand into other therapeutic areas, a persistent challenge remains: the design and optimisation of payloads. Across Sygnature Discovery , multidisciplinary teams in Canada and the UK are actively working to address these challenges. With an extensive background in small molecule chemistry, bioconjugation and protein science, these expert teams are leading efforts to place payload development at the centre of ADC innov
Alta Sciences
JUNE 6, 2025
Case Study: Two Examples of Successful Automation Integration at Altasciences for Pharmacokinetic Studies pmjackson Fri, 06/06/2025 - 09:01 By Martin Rougée, Optimization Scientist, Bioanalytical Operations Automation offers several advantages to any industry. For a contract research organization (CRO), it can play an integral role in increasing the quality and speed of drug development while reducing costs, repetitive manual tasks, and human error.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Drugs.com
JUNE 6, 2025
FRIDAY, June 6, 2025 — A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month. If approved, the shot — lenacapavir — would be given twice a year and could be a big.
Covalent Modifiers
JUNE 2, 2025
Kyle Ghaby, Benot Roux bioRxiv 2025.05.28.656658; doi: [link] There is increasing interest in the discovery of small-molecule inhibitors that form covalent bonds with their targets for therapeutic applications. Nevertheless, identifying clear rational design principles remains challenging because the action of these molecules cannot be understood as common noncovalent inhibitors.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
BioPharma Drive: Drug Pricing
MAY 31, 2025
AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its importance as a second-line treatment option.
Drug Target Review
JUNE 6, 2025
In recent years, the field of nuclear medicine has undergone a quiet revolution, particularly in its application to oncology. At the forefront of this transformation is Dr Ebrahim Delpassand, a nuclear medicine physician and the driving force behind RadioMedix (RMX), a radiopharmaceutical company focused on developing targeted diagnostics and therapies.
The Pharma Data
JUNE 6, 2025
Vertex Showcases Robust Clinical Data Supporting ALYFTREK® and the Critical Role of Sweat Chloride Reduction at 2025 European Cystic Fibrosis Conference New findings reinforce the value of CFTR modulation and the potential of ALYFTREK to enhance health outcomes and quality of life in cystic fibrosis patients Vertex Pharmaceuticals Incorporated, a global biotechnology leader in cystic fibrosis (CF) research and treatment innovation, presented a comprehensive body of new data at the 48th European
Codon
JUNE 2, 2025
The earliest painters worked as both chemists and materials scientists, discovering ways to combine natural pigments with fatty binders to yield vibrant paints. Renaissance painters moonlighted — quite literally — as anatomists. Leonardo da Vinci famously dissected some 30 corpses , in large part to aid in writing a treatise on painting , eventually compiling an understanding of human anatomy unequalled in his time.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Perficient: Drug Development
JUNE 2, 2025
In this era of Web development, Next.JS and Vercel is the powerful couple. Next.JS offers performance, scalability and flexibility in building web applications whereas Vercel provides the easy and smooth deployment experience tailored for it. Today, in this blog, we will cover the step-by-step process of deploying a Next.JS app on Vercel. We will also cover some best practices and key configurations to ensure the optimal performance in production.
BioPharma Drive: Drug Pricing
JUNE 2, 2025
The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD1 and VEGF, following Merck, and Pfizer into what’s become a competitive development race.
The Pharma Data
JUNE 6, 2025
Otsuka Unveils Promising Phase 3 Results for Sibeprenlimab in IgA Nephropathy, Marking Significant Proteinuria Reduction and Advancing a Novel APRIL-Targeted Therapy Otsuka Pharmaceutical Development & Commercialization, Inc., in collaboration with Otsuka Pharmaceutical Co., Ltd., has announced encouraging interim findings from the pivotal Phase 3 VISIONARY trial evaluating sibeprenlimab in adults with Immunoglobulin A nephropathy (IgAN), a rare and progressive autoimmune kidney disorder.
Codon
JUNE 5, 2025
It was Victoria Gray’s first time in London and, despite a sleepless plane ride across the Atlantic Ocean, she wasn’t about to skip sightseeing. While crossing Trafalgar Square, Gray paused briefly to reflect on her experience. “I would never have been able to walk this long before,” she told a NPR reporter. “I feel like I got a second chance.” Four years earlier, in 2019, Gray had become the first patient with sickle cell anemia — a genetic disorder tha
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Predictive Oncology
JUNE 3, 2025
This Executive Overview outlines the proof-of-concept study completed by Predictive Oncology to illustrate the power of our active machine learning (AI) platform paired with our biobank of over 150,000 primary patient dissociated tumor samples. The described validation results demonstrate the generation of a predictive model that was able to accurately predict drug response across 130 samples and 175 drugs.
BioPharma Drive: Drug Pricing
JUNE 2, 2025
Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a competitive corner of drug research, later this year.
The Pharma Data
JUNE 6, 2025
Sanofi Highlights Robust Pipeline of Innovations in Rare Blood Disorders at ISTH 2025 Sanofi is poised to take center stage at the 33rd Congress of the International Society on Thrombosis and Haemostasis (ISTH), set to be held in Washington, D.C., from June 21 to 25, 2025. At this premier global meeting focused on thrombosis, hemostasis, and bleeding disorders, Sanofi will present compelling data across 18 scientific abstracts, including five oral presentations.
Drug Target Review
JUNE 2, 2025
Bioconjugates are rapidly emerging as a key frontier in targeted therapies, particularly through Antibody-Drug Conjugates (ADCs) , which combine antibodies with cytotoxic drugs to deliver more precise and effective treatments. This fusion enables precise delivery of potent drugs directly to cancer cells or other targeted tissues, significantly improving the therapeutic impact while minimising harm to healthy cells.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drugs.com
JUNE 2, 2025
MONDAY, June 2, 2025 A dads eating habits can have a profound effect on their kids diets, even when those children are nothing but a twinkle in his eye, a new study says.Men who established a healthy diet as teens were more likely to model healt.
BioPharma Drive: Drug Pricing
JUNE 2, 2025
The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost to its immunology business.
The Pharma Data
JUNE 6, 2025
AstraZeneca’s Fixed-Duration Calquence Regimen Gains EU Approval for First-Line Treatment of Chronic Lymphocytic Leukaemia AstraZeneca has received European Union (EU) approval for a fixed-duration combination therapy using its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
Perficient: Drug Development
JUNE 2, 2025
Mobile App development is rapidly growing and so is the expectation of robust support. “Mobile first” is the set paradigm for many application development teams. Unlike web deployment, an app release has to go through the review process via App Store Connect and Google Play. Minor or major releases follow the app review same process, which can take 1-4 days.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drugs.com
JUNE 4, 2025
WEDNESDAY, June 4, 2025 Troubled children and teenagers are languishing hours in chaotic hospital emergency rooms, waiting for a psychiatric bed to open, a new study says.About 1 in 3 kids who go to an emergency room (ER) amid a mental health c.
BioPharma Drive: Drug Pricing
JUNE 2, 2025
Genetic research is driving progress in kidney disease drug discovery.
Science Daily: Pharmacology News
JUNE 2, 2025
A trial of an interactive game that trains people to alter their brain waves has shown promise as a treatment for nerve pain -- offering hope for a new generation of drug-free treatments.
FDA Law Blog: Biosimilars
JUNE 4, 2025
By Mark A. Tobolowsky & Ricardo Carvajal Among other things, EO 14212 established the Make America Healthy Again (MAHA) Commission (with HHS Secretary Kennedy as its Chair) and tasked it with a tall order: submission to the President of an Assessment that tackled 10(!) complex public health issues within 100(!) days. Perhaps it was inevitable that the Commission would turn to AI for help, as seems to have been the case in light of media reports that the Assessment as originally published in
Drugs.com
JUNE 6, 2025
FRIDAY, June 6, 2025 — A repurposed diabetes drug can be an effective tool against fatty liver disease, a new clinical trial has found. Dapagliflozin helped people reduce fat levels in their liver and avoid liver scarring that comes with the.
BioPharma Drive: Drug Pricing
JUNE 6, 2025
Gene therapy experts and advocates warning of the sector’s many challenges found a receptive audience in FDA leadership at a regulatory forum Thursday.
Collaborative Drug
JUNE 4, 2025
A practical guide to selecting the right ELN or LIMS for early-stage drug discovery, focusing on usability, structure search, and scalability.
Predictive Oncology
JUNE 5, 2025
Following the generation of successful results with the University of Michigan through the ACE program, Predictive Oncology is now actively calling for submissions for a new cohort of compounds to be tested in Q4 2025. ACE program participation is offered exclusively to academic institutions and provides access to the POAI proprietary active ML/AI and biobank of primary patient dissociated tumor cells (DTCs) at no-cost, with data and IP protection provided to participants.
Drugs.com
JUNE 3, 2025
TUESDAY, June 3, 2025 -- The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2. The new vaccine (mNexspike [COVID-19 Vaccine.
Drug Target Review
JUNE 5, 2025
Despite recent advances in gene therapy for sickle cell disease (SCD) , automated red blood cell exchange (aRBCX) remains a cornerstone therapy that plays a vital yet underutilised role in managing complications and enhancing quality of life for millions living with this devastating condition worldwide. Dr Aaron Haubner, Senior Manager of North America Medical Affairs and Market Access at Terumo Blood and Cell Technologies , reveals that while promising new treatments emerge, urgent partnerships
Expert insights. Personalized for you.
Let's personalize your content